Is Bliss GVS Pharma overvalued or undervalued?

As of 10 November 2025, Bliss GVS Pharma's valuation grade has moved from attractive to fair, indicating a shift in market perception. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 14.27, an EV to EBITDA of 11.61, and a PEG ratio of 0.81, which suggests that the stock is reasonably priced relative to its growth prospects.
In comparison to its peers, Bliss GVS Pharma's valuation metrics are notably lower than those of Sun Pharma, which has a PE ratio of 35.15, and Divi's Lab, which stands at 71.55. This positions Bliss GVS Pharma more favorably against its expensive counterparts while still reflecting a fair valuation overall. Despite recent underperformance compared to the Sensex, with a year-to-date return of -10.14% versus the Sensex's 6.91%, the long-term performance of 103.93% over three years suggests potential resilience in the stock.